[Comment] Screening for Barrett's oesophagus: is now the time?

Screening for cancer is an important aspect of medical practice in this new millennium. It is well accepted that to decrease mortality due to oesophageal carcinoma, it is necessary to identify the malignancy at earlier, curable stages. In The Lancet, Rebecca Fitzgerald and colleagues1 report the results of a prospective, multicentre, pragmatic, randomised controlled trial, done at 109 sociodemographically diverse general practice clinics in England, which investigated whether offering the Cytosponge-trefoil factor 3 (TFF3) procedure to patients on medication for gastro-oesophageal reflux would increase the detection of Barrett's oesophagus compared with standard management.